Abstract
We would like to comment on the recently published Letter to the Editor by R. Slavin and P. Jimenez in the Journal of Asthma (1, 2). Omalizumab is a successfully implemented supplementary therapy f...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
